Pandemic Tied to Worsening of Diabetes Outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 1, 2024 -- COVID-19 pandemic disruptions had a fairly negative impact on diabetes outcomes, according to a study published in the February issue of The Lancet Diabetes & Endocrinology.
Jamie Hartmann-Boyce, D.Phil., from University of Massachusetts Amherst, and colleagues conducted a systematic literature review to determine whether COVID-19-related disruptions to health care and lifestyles impacted diabetes management.
Based on 138 included studies (Jan. 1, 2020, to June 7, 2023), the researchers found that all-cause mortality (six studies) and diabetes-related mortality (13 studies) showed consistent increases, and most studies indicated increases in sight loss (six studies). Data for studies with an adult or mixed sample generally suggested no difference in diabetic ketoacidosis frequency or severity, while studies of children and adolescents showed increases with some due to new-onset diabetes (69 studies). In adults, data suggested decreases in hospital admissions, while there were increases in diabetes-related admissions to pediatric intensive care units (35 studies). For diabetic foot ulcer presentations (nine studies), emergency department admissions (nine studies), and overall amputation rates (20 studies), data were ambiguous. Impacts were most pronounced for females, younger people, and racial and ethnic minority groups, when evaluated.
"The review also points to the importance of ensuring all people with diabetes, but particularly those from less advantaged groups, have consistent access to diabetes medication and care," Hartmann-Boyce said in a statement.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Further Support and Information on COVID-19
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 -- Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.